| SC 13D/A | 2024-04-01 | Fairmount Funds Management LLC | Cogent Biosciences, Inc. | 9,986,556 | 9.9% | EDGAR |
| SC 13D/A | 2024-03-27 | Fairmount Funds Management LLC | Cogent Biosciences, Inc. | 9,986,556 | 9.9% | EDGAR |
| SC 13D/A | 2024-02-16 | Fairmount Funds Management LLC | Cogent Biosciences, Inc. | 23,079,141 | 18.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Point72 Asset Management, L.P. | Cogent Biosciences, Inc. | 5,191,448 | 6.0% | EDGAR |
| SC 13G/A | 2024-02-14 | RA CAPITAL MANAGEMENT, L.P. | Cogent Biosciences, Inc. | 0 | 0.0% | EDGAR |
| SC 13G/A | 2024-02-14 | Venrock Healthcare Capital Partners II, L.P. | Cogent Biosciences, Inc. | 9,038,844 | 10.0% | EDGAR |
| SC 13G/A | 2024-02-14 | COMMODORE CAPITAL LP | Cogent Biosciences, Inc. | 6,172,086 | 7.1% | EDGAR |
| SC 13G | 2024-02-14 | Kynam Capital Management, LP | Cogent Biosciences, Inc. | 5,854,766 | 6.8% | EDGAR |
| SC 13G | 2024-02-13 | VANGUARD GROUP INC | Cogent Biosciences, Inc. | 4,534,655 | 5.3% | EDGAR |
| SC 13G/A | 2024-02-09 | TCG Crossover GP I, LLC | Cogent Biosciences, Inc. | 5,631,042 | 6.5% | EDGAR |
| SC 13G | 2024-02-09 | FMR LLC | Cogent Biosciences, Inc. | 5,302,854 | 6.2% | EDGAR |
| SC 13G | 2024-02-05 | SUVRETTA CAPITAL MANAGEMENT, LLC | Cogent Biosciences, Inc. | 5,481,034 | 6.4% | EDGAR |
| SC 13G/A | 2024-01-26 | BlackRock Inc. | Cogent Biosciences, Inc. | 6,755,584 | 7.8% | EDGAR |
| SC 13G/A | 2024-01-23 | STATE STREET CORP | Cogent Biosciences, Inc. | - | 4.8% | EDGAR |
| SC 13D/A | 2023-06-13 | Fairmount Funds Management LLC | Cogent Biosciences, Inc. | 19,962,564 | 20.0% | EDGAR |
| SC 13G | 2023-06-01 | Point72 Asset Management, L.P. | Cogent Biosciences, Inc. | 3,562,902 | 5.0% | EDGAR |
| SC 13G/A | 2023-02-14 | BIOTECHNOLOGY VALUE FUND L P | Cogent Biosciences, Inc. | 527,632 | 1.3% | EDGAR |
| SC 13G/A | 2023-02-14 | RA CAPITAL MANAGEMENT, L.P. | Cogent Biosciences, Inc. | 5,999,481 | 8.6% | EDGAR |
| SC 13G/A | 2023-02-14 | Venrock Healthcare Capital Partners II, L.P. | Cogent Biosciences, Inc. | 7,309,128 | 10.0% | EDGAR |
| SC 13G/A | 2023-02-14 | Frazier Life Sciences Public Fund, L.P. | Cogent Biosciences, Inc. | 2,102,434 | 3.0% | EDGAR |